Immunoprophylaxis of respiratory syncytial virus: global experience
Open Access
- 24 June 2002
- journal article
- review article
- Published by Springer Nature in Respiratory Research
- Vol. 3 (S1) , 6-S33
- https://doi.org/10.1186/rr187
Abstract
Respiratory syncytial virus (RSV) infects nearly all children by age 2 years, and it causes considerable illness and death in certain high-risk pediatric populations. Historically, treatment for RSV has been symptomatic, and developing a safe and effective vaccine has been a challenge. Therefore, research efforts have turned to passive immunization as the best option to control RSV. Palivizumab, a genetically engineered humanized monoclonal antibody, has been shown to reduce RSV-related hospitalizations significantly, with few adverse effects. It was approved for use in high-risk children in the USA in 1998 and in Europe in 1999; it is now approved for use in more than 45 countries. The efficacy and safety of palivizumab continue to be supported by both clinical trial and outcomes data.Keywords
This publication has 43 references indexed in Scilit:
- The use of palivizumab monoclonal antibodyto control an outbreak of respiratory syncytial virus infection in a special care baby unitJournal of Hospital Infection, 2001
- SAFETY AND TOLERANCE OF PALIVIZUMAB ADMINISTRATION IN A LARGE NORTHERN HEMISPHERE TRIALThe Pediatric Infectious Disease Journal, 2001
- Bronchiolitis‐Associated Mortality and Estimates of Respiratory Syncytial Virus–Associated Deaths among US Children, 1979–1997The Journal of Infectious Diseases, 2001
- Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus seasonThe Pediatric Infectious Disease Journal, 2000
- A Direct Comparison of the Activities of Two Humanized Respiratory Syncytial Virus Monoclonal Antibodies: MEDI‐493 and RSHZl9The Journal of Infectious Diseases, 1999
- Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIVPediatrics, 1998
- Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart diseaseThe Journal of Pediatrics, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- From the National Institute of Allergy and Infectious Diseases and the World Health Organization: Respiratory Syncytial and Parainfluenza VirusesThe Journal of Infectious Diseases, 1990
- Possible Transmission by Fomites of Respiratory Syncytial VirusThe Journal of Infectious Diseases, 1980